IntraLinks
® (NYSE: IL), a global technology provider of inter-enterprise content management and collaboration solutions, announced that
Actelion Pharmaceuticals Ltd
, an Allschwil/Basel, Switzerland headquartered biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments to serve unmet medical needs, has selected IntraLinks Connect℠ to streamline its documentation exchange during clinical trials.
Prior to engaging IntraLinks, Actelion relied on traditional courier services to facilitate the exchange of sensitive clinical trial documentation between sponsors and participants, resulting in excessive shipping costs and manual processes for tracking and other activities.
To streamline its documentation process and gain efficiency for themselves and their investigators, Actelion chose IntraLinks Connect to provide central clinical trial portals to facilitate the more secure, compliant auditable exchange of site feasibility, study start up, study conduct and study close-out documentation.
IntraLinks Connect’s security, detailed reporting, workflows, and analytics, together with IntraLinks’ knowledgeable professional service support convinced Actelion that IntraLinks provided the best fit to its requirements. “Whilst working with IntraLinks we can see the maturity of its technology and the commitment of the team to support Actelion moving forward in this area,” said Christine Schwenninger, Head of Global Clinical Monitoring, Actelion. “We are looking forward to working closely together with IntraLinks in the coming years.”
“Actelion’s engagement of IntraLinks demonstrates the growing demand for secure information exchange within the clinical trial process,” says Andy Watson, VP of life sciences EMA at IntraLinks. “IntraLinks Connect will provide Actelion greater efficiency, traceability, and security to improve communication, collaboration, and document exchange between everyone involved in the clinical trial.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.